Capital Fund Management S.A. Invests $793,000 in Omnicell, Inc. $OMCL

Capital Fund Management S.A. purchased a new position in Omnicell, Inc. (NASDAQ:OMCL) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 22,682 shares of the company’s stock, valued at approximately $793,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of OMCL. Lazard Asset Management LLC lifted its stake in shares of Omnicell by 81.6% in the fourth quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company’s stock worth $73,093,000 after buying an additional 737,536 shares in the last quarter. Toronto Dominion Bank purchased a new position in shares of Omnicell in the fourth quarter worth about $30,637,000. Dimensional Fund Advisors LP lifted its stake in shares of Omnicell by 31.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company’s stock worth $73,127,000 after buying an additional 394,820 shares in the last quarter. Pacer Advisors Inc. purchased a new position in shares of Omnicell in the first quarter worth about $10,542,000. Finally, Nuveen LLC purchased a new stake in shares of Omnicell in the first quarter valued at about $6,218,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

Omnicell Stock Down 1.1%

Shares of OMCL opened at $32.72 on Wednesday. The firm has a market cap of $1.50 billion, a P/E ratio of 65.44, a price-to-earnings-growth ratio of 7.23 and a beta of 0.78. Omnicell, Inc. has a 12-month low of $22.66 and a 12-month high of $55.74. The company’s 50-day moving average price is $29.78 and its 200 day moving average price is $31.74. The company has a current ratio of 1.42, a quick ratio of 1.24 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.30 by $0.15. The firm had revenue of $290.56 million for the quarter, compared to analyst estimates of $275.57 million. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. Omnicell’s revenue was up 5.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.51 EPS. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. On average, sell-side analysts forecast that Omnicell, Inc. will post 1.09 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Benchmark reduced their target price on shares of Omnicell from $62.00 to $40.00 and set a “buy” rating on the stock in a research note on Wednesday, May 7th. Bank of America lifted their target price on shares of Omnicell from $30.00 to $34.00 and gave the stock a “neutral” rating in a research note on Friday, May 23rd. Piper Sandler reduced their target price on shares of Omnicell from $57.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, August 11th. Wall Street Zen downgraded shares of Omnicell from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 9th. Finally, Wells Fargo & Company lifted their target price on shares of Omnicell from $37.00 to $40.00 and gave the stock an “overweight” rating in a research note on Monday, July 21st. Four investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, Omnicell currently has a consensus rating of “Moderate Buy” and a consensus price target of $46.71.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.